Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports

01-07-2017 | Antiphospholipid Syndrome (S Zuily, Section Editor)

Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome—Biomarkers of the Disease and Biopharmaceuticals

Author: Mirjana Bećarević

Published in: Current Rheumatology Reports | Issue 7/2017

Login to get access

Abstract

Purpose of Review

Laboratory criterion for the diagnosis of antiphospholipid syndrome (APS) is the presence of antiphospholipid antibodies (aPL Abs). Complement system has a role in mediating aPL Abs-induced thrombosis in animal models. The importance of antibodies against complement components (potential biomarkers of APS) and the importance of antibodies with beneficial anti-complement effects in APS (as biopharmaceuticals) are reviewed.

Recent Findings

Antibodies against complement components described in APS patients, so far, are anti-C1q and anti-factor H Abs, although anti-factor B Abs and anti-C5a Abs were described in animal models of APS. Clinical studies in APS patients are limited to a small number of case reports.

Summary

Studies that would confirm potential role of Abs against complement components (as potential biomarkers of APS) are lacking. Lack of randomized clinical trials (that would provide complete data for confirmation of beneficial effects of biopharmaceuticals in complement inhibition) in APS is alarming.
Literature
1.
Bertolaccini ML, Ammengual O, Andreolii L, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014;13:917–30.CrossRefPubMed
2.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.CrossRefPubMed
3.
van den Hoogen LL, van Roon JAG, Radstake TRDJ, et al. Delineating the deranged immune system in the antiphospholipid syndrome. Autoimmun Rev. 2016;15:50–60.CrossRefPubMed
4.
Rodríguez-Pintó I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016;15:1120–4.CrossRefPubMed
5.
Rodriguez-Pinto I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: the current management approach. Best Pract Res Clin Rheum. 2016;30:239–49.CrossRef
6.
Shapira I, Andrade D, Allen SL, Salmon JE. Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthrithis Rheum. 2012;64(8):2719–23.CrossRef
7.
Espinosa G, Berman H, Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev. 2011;10:664–8.CrossRefPubMed
8.
D’Ippolito S, Meroni PL, Koike T, Veglia M, Scambia G, Di Simone N. Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun Rev. 2014;13:901–8.CrossRefPubMed
9.
Galarza-Maldonado C, Kourilovitch MR, Perez-Fernandez OM, Gaybor M, Cordero C, Cabrera C, et al. Obstetric antiphospholipid syndrome. Autoimmun Rev. 2012;11:288–95.CrossRefPubMed
10.
Meroni PL, Raschi E, Grossi E, Pregnolato F, Traspidi L, Acaia B, et al. Obstetric and vascular APS: same autoantibodies but different diseases? Lupus. 2012;21:708–10.CrossRefPubMed
11.
Cavazzana I, Manuela N, Irene C, Barbara A, Sara S, Orietta BM, et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? J Autoimmun. 2007;28:160–4.CrossRefPubMed
12.
•• Melis JPM, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PWHI. Complement in therapy and disease regulating the complement system with antibody-based therapeutics. Mol Immunol. 2015;67:117–30. Showed the importance of Ab-based drugs that increase or decrease the complement system CrossRefPubMed
13.
Mollnes TE, Kirschfink M. Strategies of therapeutic complement inhibition. Mol Immunol. 2006;43:107–21.CrossRefPubMed
14.
15.
Abbas AK, Lichtmann AH, Pober JC. Cellular and molecular immunology. Philadelphia: WB Saunders Company; 2015.
16.
17.
Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007;40:560–6.CrossRefPubMed
18.
Sevciovic Grumach A, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol. 2014;61:110–7.CrossRef
19.
Peerschke EIB, Yin W, Alpert DR, Roubey RAS, Salmon JE, Ghebrehiwet B. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus. 2009;18:530–8.CrossRefPubMedPubMedCentral
20.
Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47:2170–5.CrossRefPubMedPubMedCentral
21.
Thurman J, Kraus D, Girardi G, et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol. 2005;42:87–97.CrossRefPubMed
22.
Carrera-Marın AL, Romay-Penabad Z, Papalardo E, Reyes-Maldonado E, Garcıa-Latorrem E, Vargas G, et al. C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies. Lupus. 2012;21:1497–505.CrossRefPubMed
23.
24.
Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus. 2003;12:535–8.CrossRefPubMed
25.
•• Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis. 2002;61:46–50. One of the earliest reports that showed that complement activation is a mediator of aPL Abs-induced pregnancy losses and thrombosis CrossRef
26.
Pierangeli S, Vega-Ostertag M, Liu X, Girardi G. Complement activation: a novel mechanism in the antiphospholipid syndrome. Ann N Y Acad Sci. 2005;1051:413–20.CrossRefPubMed
27.
Pierangeli S, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005;52:2120–4.CrossRefPubMed
28.
Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003;112:1644–54.CrossRefPubMedPubMedCentral
29.
Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to b2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005;106:2340–6.CrossRefPubMed
30.
Arfors L, Lefvert AK. Enrichment of antibodies against phospholipids in circulating immune complexes (CIC) in the anti-phospholipid syndrome (APLS). Clin Exp Immunol. 1997;108:47–51.CrossRefPubMedPubMedCentral
31.
Sammaritano LR, Ng S, Sobel R, et al. Anticardiolipin IgG subclasses. Association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum. 1997;40:1998–2006.CrossRefPubMed
32.
Amengual O, Atsumi T, Khamashta MA, Bertolaccini ML, Hughes GVR. IgG2 restriction of anti-P-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: comment on the article by Sammaritano et a1. Arthritis Rheum. 1998;41:1513–20.CrossRefPubMed
33.
Guerin J, Casey E, Feighery C, et al. Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity. 1999;31:109–16.CrossRefPubMed
34.
Samarkos M, Davies KA, Gordon C, Walport MJ, Loizou S. IgG subclass distribution of antibodies against b2gpI and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology. 2001;40:1026–32.CrossRefPubMed
35.
Païdassi H, Tacnet-Delorme P, Garlatti V, et al. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol. 2008;180:2329–38.CrossRefPubMedPubMedCentral
36.
Gropp K, Weber N, Reuter M, et al. Beta (2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood. 2011;118:2774–83.CrossRefPubMed
37.
Skerka C, Gropp K, Weber N, Reuter M, Micklisch S, Kopka I, Hallstroem T, Skerka C. Beta 2 glycoprotein 1 (beta 2GPI), the major target in anti-phospholipid syndrome (APS), regulates complement activation on the level of C3/C3b. Abstracts/Mol Immunol. 2011;48:1666–733.
38.
Johnson E, Hetland G. Human umbilical vein endothelial cell synthesize functional C3, C5, C6, C8 and C9 in vivo. Scand J Immunol. 1991;33:667–71.CrossRefPubMed
39.
van den Berg RH, Faber-Krol MC, Sim RB, Daha MR. The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol. 1998;161:6924–30.PubMed
40.
Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. 2009;68:1030–5.CrossRefPubMed
41.
Bećarević M, Majkić-Singh N. High-sensitivity C-reactive protein: discriminator between patients with primary and secondary antiphospholipid syndrome. Clin Biochem. 2008;41:1449–53.CrossRefPubMed
42.
Oku K, Amengual O, Hisada R, et al. Autoantibodies against complement component 1 q subcomponent (C1q) contribute to complement activation and recurrent thrombosis/pregnancy morbidity in antiphospholipid syndrome. Rheumatology (Oxford). 2016;55:1403–11.CrossRef
43.
Navratil JS, Manzi S, Kao AH, Krishnaswami S, Liu CC, Ruffing MJ, Shaw PS, et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum. 2006;54:670–4.CrossRefPubMed
44.
Bećarević M, Ignjatović S. Proinflammatory proteins in female and male patients with primary antiphospholipid syndrome: preliminary data. Clin Rheumatol. 2016;35:2477–83.CrossRefPubMed
45.
• Barratt-Due A, Fløisand Y, Orrem HL, Kvam AK, Holme PA, Bergseth G, et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology. 2016;55:1337–9. Showed that complement inhibition is a “life-saving” medical intervention for patients with CAPS CrossRefPubMedPubMedCentral
46.
•• Dragon-Durey MA, Blanc C, Marinozzi MC, van Schaarenburg RA, Trouw LA. Autoantibodies against complement components and functional consequences. Mol Immunol. 2013;56:213–21. Described auto Abs against various complement components and their associations with clinical manifestations of various diseases CrossRefPubMed
47.
Daha NA, Banda NK, Roos A, Beurskens FJ, Bakker JM, Daha MR, Trouw LA. Complement activation by (auto-) antibodies. Mol Immunol. 2011;48:1656–65.CrossRefPubMed
48.
49.
Katsumata Y, Miyake K, Kawaguchi Y, et al. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum. 2011;63:2436–44.CrossRefPubMed
50.
Blanc C, Togarsimalemath SK, Chauvet S, et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol. 2015;194:5129–38.CrossRefPubMed
51.
Foltyn Zadura A, Memon AA, Stojanovich LJ, et al. Factor H autoantibodies in patients with antiphospholipid syndrome and thrombosis. J Rheumatol. 2015;42:1786–93.CrossRefPubMed
52.
Khamashta M, Taraborelli M, Sciascia S, Tincani A. Antiphospholipid syndrome. Best Pract Res Clin Rheumatol. 2016;30:133–48.CrossRefPubMed
53.
Zhou XJ, Chen M, Wang SX, Zhou FD, Zhao MH. A 3-year follow-up of a patient with acute renal failure caused by thrombotic microangiopathy related to antiphospholipid syndrome: case report. Lupus. 2016;0:1–6.
54.
Thachil J. Recurrent venous thromboembolism while on anticoagulant therapy. Blood Rev. 2012;26:175–81.CrossRefPubMed
55.
Jordan SC, Choi J, Kahwaji J, Vo A. Complement inhibition for prevention and treatment of antibody-mediated rejection in renal allograft recipients. Transplant Proc. 2016;48:806–8.CrossRefPubMed
56.
Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation—a case report. Transplant Proc. 2011;43:2097–101.CrossRefPubMed
57.
Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol. 2013;148:313–21.CrossRefPubMed
58.
Hallstensen RF, Bergseth G, Foss S, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. 2015;220:452–9.CrossRefPubMed
59.
Kocak B, Arpali E, Demiralp E, Yelken B, Karatas C, Gorcin S, et al. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant Proc. 2013;45:1022–5.CrossRefPubMed
60.
Legendre C, Sberro-Soussan R, Zuber J, Rabant M, Loupy A, Timsit MA, Anglicheau D. Eculizumab in renal transplantation. Transplant Rev. 2013;27:90–2.CrossRef
61.
Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmun Rev. 2011;11:56–60.CrossRefPubMed
62.
Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L, Cook HT, Cairns TD. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology. 2015;54:2288–90.
63.
Stewart ZA, Collins TE, Schlueter AJ, Raife TI, Holanda DG, Nair R, Reed AI, Thomas CP. Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc. 2012;44:3033–6.CrossRefPubMed
64.
Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362:1744–5.CrossRefPubMed
65.
Gustavsen A, Bergseth G, Volokhina E, van den Heuvel LP, Skattum L, Mollnes TE, Barratt-Due A. Eculizumab treatment in pregnancy complicated with APS—effects on mother and infant. Abstracts/Immunobiology. 2016;221:1131–225.
66.
Wig S, Chan M, Thachil J, Bruce J, Barnes T. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology. 2016;55:382–4.CrossRefPubMed
67.
Sheridan D, Yu ZX, Zhang Y, Patel R, Lasaro M, Bouchard K, Andrien B, Marozsan A, Wang Y, Tamburini P. Design and preclinical characterization of ALXN 1210: a next generation anti-C5 monoclonal antibody with improved pharmacokinetics and duration of action. Abstracts/Immunobiology. 2016;221:1131–225.
68.
Harder MJ, Kuhn N, Schrezenmeier H, et al. Mechanistic evidence for incomplete terminal pathway inhibition under eculizumab during strong complement activation. Abstracts/Immunobiology. 2016;221:1131–225.
70.
Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, et al. Genetic variants in C5 and poor response to eculizumab. New Engl J Med. 2014;370:632–9.CrossRefPubMed
71.
Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: past, present and future. Semin Immunol. 2016;28:223–40.CrossRefPubMed
72.
Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5–C5a receptor axis. Mol Immunol. 2011;48:1631–42.CrossRefPubMed
73.
Manthey HD, Woodruff TM, Taylor SM, Monk PM. Complement 801 component 5a (C5a). Intern J Biochem Cell Biol 2009;41:2114-7.
Metadata
Title
Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome—Biomarkers of the Disease and Biopharmaceuticals
Author
Mirjana Bećarević
Publication date
01-07-2017
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 7/2017
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-017-0669-1

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits